Clinical trial
Epilepsy, Immune Dysfunction and Risk of Infection Study - A Prospective Cohort Study of Immune Dysfunction and Infection Risk With Epilepsy
NCT07903168 is registered in ClinicalTrials.gov with University of Aberdeen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Epilepsy, Immune Dysfunction and Risk of Infection Study - A Prospective Cohort Study of Immune Dysfunction and Infection Risk With Epilepsy
- Lead sponsor
- University of Aberdeen
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 4, 2026
- Completion date
- May 31, 2038
- Enrollment
- 500 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
antiepileptic drugs, epilepsy, immune dysfunction, infection
Arms
As registered; 2 arms.
-
Exposed
Individuals taking antiseizure medications
-
Unexposed
Individuals not taking antiseizure medications
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Infections
Clinically significant rates of infection (community antimicrobial prescriptions or hospital admissions with infection)
Lead sponsor's other trials
University of Aberdeen, most recent start first.
+170 more trials See the organization page
Similar trials
Same condition (Epilepsy) and phase, most recent start first.
+534 more trials See the condition page